NCT03228836View on ClinicalTrials.gov

Efficacy and Safety Evaluation of IBI308 in Patients With Extranodal NK/T Cell Lymphoma Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

August 23, 2017

Primary Completion Date

February 28, 2020

Study Completion Date

February 28, 2020

Conditions
Effect of Drugs
Interventions
DRUG

Sintilimab

Sintilimab (IBI308) 200mg IV Q3W

Trial Locations (1)

Unknown

Jiangsu Provincial Hospital, Nanjing

All Listed Sponsors
lead

Innovent Biologics (Suzhou) Co. Ltd.

INDUSTRY

NCT03228836 - Efficacy and Safety Evaluation of IBI308 in Patients With Extranodal NK/T Cell Lymphoma Patients | Biotech Hunter | Biotech Hunter